DIEM DANG: Open Payments
NPI 1255819991 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$985 in 39 payments from 10 companies in 2025. Trend: 2023 $460 · 2024 $745 · 2025 $985
Food & beverage: $916Education: $69
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 7 | $188 |
| AstraZeneca Pharmaceuticals LP | 2 | $172 |
| Novo Nordisk Inc | 9 | $162 |
| Xeris Pharmaceuticals, Inc. | 5 | $111 |
| Lilly USA, LLC | 5 | $96 |
| Astellas Pharma US Inc | 2 | $92 |
| PFIZER INC. | 5 | $89 |
| Abbott Laboratories | 2 | $33 |
| ABBVIE INC. | 1 | $23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
Products named: AIRSUPRA, REPATHA, RECORLEV, Ozempic, PREVNAR 20, JARDIANCE, MOUNJARO, OTEZLA.
Industry payments across TX — which companies pay providers there.
